Literature DB >> 21479973

Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii.

R López-Rojas1, F Docobo-Pérez, M E Pachón-Ibáñez, B G de la Torre, M Fernández-Reyes, C March, J A Bengoechea, D Andreu, L Rivas, J Pachón.   

Abstract

Pan-resistant Acinetobacter baumannii have prompted the search for therapeutic alternatives. We evaluate the efficacy of four cecropin A-melittin hybrid peptides (CA-M) in vivo. Toxicity was determined in mouse erythrocytes and in mice (lethal dose parameters were LD(0), LD(50), LD(100)). Protective dose 50 (PD(50)) was determined by inoculating groups of ten mice with the minimal lethal dose of A. baumannii (BMLD) and treating with doses of each CA-M from 0.5 mg/kg to LD(0). The activity of CA-Ms against A. baumannii was assessed in a peritoneal sepsis model. Mice were sacrificed at 0 and 1, 3, 5, and 7-h post-treatment. Spleen and peritoneal fluid bacterial concentrations were measured. CA(1-8)M(1-18) was the less haemolytic on mouse erythrocytes. LD(0) (mg/kg) was 32 for CA(1-8)M(1-18), CA(1-7)M(2-9), and Oct-CA(1-7)M(2-9), and 16 for CA(1-7)M(5-9). PD(50) was not achieved with non-toxic doses (≤ LD(0)). In the sepsis model, all CA-Ms were bacteriostatic in spleen, and decreased bacterial concentration (p < 0.05) in peritoneal fluid, at 1-h post-treatment; at later times, bacterial regrowth was observed in peritoneal fluid. CA-Ms showed local short-term efficacy in the peritoneal sepsis model caused by pan-resistant Acinetobacter baumannii.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21479973     DOI: 10.1007/s10096-011-1233-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  35 in total

1.  N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide.

Authors:  C Chicharro; C Granata; R Lozano; D Andreu; L Rivas
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

2.  Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii.

Authors:  María Jesús Rodríguez-Hernández; José Saugar; Fernando Docobo-Pérez; Beatriz G de la Torre; María Eugenia Pachón-Ibáñez; Andrés García-Curiel; Felipe Fernández-Cuenca; David Andreu; Luis Rivas; Jerónimo Pachón
Journal:  J Antimicrob Chemother       Date:  2006-04-24       Impact factor: 5.790

3.  Determinants of recombinant production of antimicrobial cationic peptides and creation of peptide variants in bacteria.

Authors:  L Zhang; T Falla; M Wu; S Fidai; J Burian; W Kay; R E Hancock
Journal:  Biochem Biophys Res Commun       Date:  1998-06-29       Impact factor: 3.575

4.  Cecropin A-derived peptides are potent inhibitors of fungal plant pathogens.

Authors:  L Cavallarin; D Andreu; B San Segundo
Journal:  Mol Plant Microbe Interact       Date:  1998-03       Impact factor: 4.171

Review 5.  The world of beta- and gamma-peptides comprised of homologated proteinogenic amino acids and other components.

Authors:  Dieter Seebach; Albert K Beck; Daniel J Bierbaum
Journal:  Chem Biodivers       Date:  2004-08       Impact factor: 2.408

Review 6.  Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.

Authors:  L Poirel; P Nordmann
Journal:  Clin Microbiol Infect       Date:  2006-09       Impact factor: 8.067

7.  Antiendotoxin activity of cationic peptide antimicrobial agents.

Authors:  M Gough; R E Hancock; N M Kelly
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

Review 8.  Acinetobacter outbreaks, 1977-2000.

Authors:  Maria Virginia Villegas; Alan I Hartstein
Journal:  Infect Control Hosp Epidemiol       Date:  2003-04       Impact factor: 3.254

9.  Genetic diversity of carbapenem-resistant isolates of Acinetobacter baumannii in Europe.

Authors:  K J Towner; K Levi; M Vlassiadi
Journal:  Clin Microbiol Infect       Date:  2007-12-18       Impact factor: 8.067

10.  Chemical synthesis and enzymic processing of precursor forms of cecropins A and B.

Authors:  H C Boman; I A Boman; D Andreu; Z Q Li; R B Merrifield; G Schlenstedt; R Zimmermann
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

View more
  13 in total

1.  The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model.

Authors:  Rebekah Henry; Bethany Crane; David Powell; Deanna Deveson Lucas; Zhifeng Li; Jesús Aranda; Paul Harrison; Roger L Nation; Ben Adler; Marina Harper; John D Boyce; Jian Li
Journal:  J Antimicrob Chemother       Date:  2015-01-14       Impact factor: 5.790

2.  Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii.

Authors:  Younes Smani; Juan Domínguez-Herrera; José Ibáñez-Martínez; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

3.  Potential Mechanisms of Mucin-Enhanced Acinetobacter baumannii Virulence in the Mouse Model of Intraperitoneal Infection.

Authors:  Greg Harris; Bruce E Holbein; Hongyan Zhou; H Howard Xu; Wangxue Chen
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

4.  Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant Acinetobacter baumannii strains.

Authors:  Ramamourthy Gopal; Young Gwon Kim; Jun Ho Lee; Seog Ki Lee; Jeong Don Chae; Byoung Kwan Son; Chang Ho Seo; Yoonkyung Park
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

5.  Severe Acinetobacter baumannii sepsis is associated with elevation of pentraxin 3.

Authors:  Patrick M Ketter; M Neal Guentzel; Beverly Schaffer; Maryanne Herzig; Xiaowu Wu; Robbie K Montgomery; Bijaya K Parida; Chriselda G Fedyk; Jieh-Juen Yu; James Jorgensen; James P Chambers; Andrew P Cap; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2014-07-07       Impact factor: 3.441

6.  Epinecidin-1 has immunomodulatory effects, facilitating its therapeutic use in a mouse model of Pseudomonas aeruginosa sepsis.

Authors:  Chieh-Yu Pan; Jian-Chyi Chen; Jenn-Feng Sheen; Tai-Lang Lin; Jyh-Yih Chen
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

7.  The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace.

Authors:  Ignasi Roca; Paula Espinal; Xavier Vila-Farrés; Jordi Vila
Journal:  Front Microbiol       Date:  2012-04-23       Impact factor: 5.640

Review 8.  Antimicrobial peptides: a new class of antimalarial drugs?

Authors:  Nuno Vale; Luísa Aguiar; Paula Gomes
Journal:  Front Pharmacol       Date:  2014-12-19       Impact factor: 5.810

Review 9.  Nanoparticles for Control of Biofilms of Acinetobacter Species.

Authors:  Richa Singh; Shradhda Nadhe; Sweety Wadhwani; Utkarsha Shedbalkar; Balu Ananda Chopade
Journal:  Materials (Basel)       Date:  2016-05-18       Impact factor: 3.623

10.  Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection.

Authors:  Tao Pan; Xiaoyun Liu; Shougui Xiang; Wenli Ji
Journal:  Exp Ther Med       Date:  2016-02-08       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.